Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 6/20 | 0.37 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107050 | 0.90 | ESR2 (0.44) | ESR2ACHEL3MBTL1ALDH1A1 | |
| SCHEMBL10102170 | 0.84 | ESR2 (0.41) | ESR2BCHEACHEJAK2JAK1 | |
| SCHEMBL10102164 | 0.79 | ACHE (0.36) | BCHEACHEL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10106836 | 0.75 | ESR2 (0.41) | ESR2JAK2JAK1L3MBTL1ALDH1A1 | |
| SCHEMBL10101848 | 0.70 | ACHE (0.43) | BCHEACHETSHRTYRSMN1; SMN2 | |
| SCHEMBL10102162 | 0.68 | SYK (0.34) | BCHEACHEL3MBTL1ALDH1A1 | |
| SCHEMBL14042199 | 0.68 | HIF1A (0.46) | ACHEL3MBTL1 | |
| SCHEMBL4221494 | 0.68 | ESR2 (0.48) | ESR2JAK2JAK1SLC6A2SLC6A4 | |
| SCHEMBL1326832 | 0.68 | ESR2 (0.48) | ESR2JAK2JAK1SLC6A3 | |
| SCHEMBL1327835 | 0.68 | ESR2 (0.50) | ESR2JAK2JAK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | ESR2 75/4885BCHE 2145/4885ACHE 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.